Author Archives: admin


Stem Cell Clinic > Articles by: admin

COVID-19 UPDATE : Global Human Embryonic Stem Cell Market 2020 Comprehensive Study with Arizona Board of Regents, STEMCELL Technologies Inc, Cellular…

By Embryonic Stem Cells

The Global Human Embryonic Stem Cell Market report demonstrates supportive data related to the dominant players in the market such as product offerings, revenue, segmentation, and business synopsis. The report gives helpful insights which assist while launching a new product. This global market research report has complete overview of the market, covering various aspects such as product definition, segmentation based on various parameters, and the prevailing vendor landscape. Moreover, in the Global Human Embryonic Stem Cell Market report, the key product categories are also included. The report also analyses the emerging trends along with major drivers, challenges and opportunities in the Global Human Embryonic Stem Cell Market.

The Global Human Embryonic Stem Cell Market study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate, and general attractiveness. To understand the competitive landscape in the market, an analysis of Porters five forces model for the market has also been included. Furthermore, businesses can decide upon the strategies about the product, customer, key player, sales, promotion or marketing by acquiring a detailed analysis of competitive markets. The Global Human Embryonic Stem Cell Market report is a synopsis about how is the market status right now and how will it be in the forecast years for industry.

Human embryonic stem cell market estimated to register a healthy CAGR of 10.5% in the forecast period of 2019 to 2026. The imminent market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026. The growth of the market can be attributed to the increase in tissue engineering process.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-human-embryonic-stem-cell-market

Key Market Competitors:

Some of the major companies functioning in global human embryonic stem cell market are Arizona Board of Regents, STEMCELL Technologies Inc, Cellular Engineering Technologies, CellGenix GmbH, PromoCell GmbH, Lonza, Kite Pharma, Takeda Pharmaceutical Company Limited, BrainStorm Cell Limited., CELGENE CORPORATION, Osiris Therapeutics,Inc, U.S. Stem Cell, Inc, Waisman Biomanufacturing, Caladrius, Pfizer Inc., Thermo Fisher Scientific, Merck KGaA, Novo Nordisk A/S, Johnson & Johnson Services, Inc and SA Biosciences Corporation among others.

Global Human Embryonic Stem Cell Market By Type (Totipotent Stem Cells, Pluripotent Stem Cells, Unipotent Stem Cells), Application (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing), End User (Research, Clinical Trials, Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Industry Trends and Forecast to 2026

Key Developments in the Market:

In January 2019, STEMCELL Technologies, launched mTeSR Plus, a Next-generation culture system for human embryo system and IPS cell maintenance. This launch will able to promote more consistent cell culture environment through sustained medium pH and stabilized components In January, 2018 Mayo Foundation for Medical Education and Research, got approval on the tool named as automated bioreactor. This tool can manufacture the stem cells, in billions within a day. This will allow the company to harvest the cell from bone marrow, this will allow the treatment of patients when their own cell is not in use, which will allow the Mayo Clinic to accelerate its existing studies using stem cells

Market Definition: Global Human Embryonic Stem Cell Market

Human embryonic stem cell is pluripotent stem cells, derivative of inner cell of blastocyst from inner cell mass of embryo. Embryonic stem cell gives rise to somatic cells in embryo. This is a useful tool to understand the difficult process mechanism involved in growth of specialized cells and establishment of organ structures, which are alternative to cancer therapy.

Market Drivers

Increase prevalence of cardiac and malignant diseases is driving the market growth Growing R&D investments and research initiatives which will propel the market in the forecast period High requirement for regenerative medicines is acting as a catalyst for growth of the market Support from government in funding and regulation can also boost the market growth

Market Restraints

Costly procedures and regulatory complications is acting as a restraint for the market growth Strict regulatory guidelines is hindering the growth of the market Ethical and policy concern may hamper the market in the forecast period

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-human-embryonic-stem-cell-market

Table of Contents-Snapshot Executive Summary Chapter 1 Industry Overview Chapter 2 Industry Competition by Manufacturers Chapter 3 Industry Production Market Share by Regions Chapter 4 Industry Consumption by Regions Chapter 5 Industry Production, Revenue, Price Trend by Type Chapter 6 Industry Analysis by Applications Chapter 7 Company Profiles and Key Figures in Industry Business Chapter 8 Industry Manufacturing Cost Analysis Chapter 9 Marketing Channel, Distributors and Customers Chapter 10 Market Dynamics Chapter 11 Industry Forecast Chapter 12 Research Findings and Conclusion Chapter 13 Methodology and Data Source.

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-human-embryonic-stem-cell-market

The current trend pertaining to the demand supply and sales together with the recent developments have been given here to provide an exhaustive picture of this market. It also allows voluntarily accessible affordable reports of the research that is the end result of the personalized research carried by the internal team of professionals.

To comprehend Global Human Embryonic Stem Cell market dynamics in the world mainly, the worldwide Human Embryonic Stem Cell market is analyzed across major global regions.

North America: United States, Canada, and Mexico. South & Central America: Argentina, Chile, and Brazil. Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa. Europe: UK, France, Italy, Germany, Spain, and Russia. Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

Segmentation: Global Human Embryonic Stem Cell Market

By Type

Totipotent Stem Cells Pluripotent Stem Cells Unipotent Stem Cells

By Application

Regenerative Medicine Stem Cell Biology Research Tissue Engineering Toxicology Testing

By End User

Research Clinical Trials Others

Reasons to Purchase this Report

Current and future of global human embryonic stem cell market outlook in the developed and emerging markets The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period Regions/Countries that are expected to witness the fastest growth rates during the forecast period The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

All segmentation provided above in this report is represented at country level All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

View original post here:
COVID-19 UPDATE : Global Human Embryonic Stem Cell Market 2020 Comprehensive Study with Arizona Board of Regents, STEMCELL Technologies Inc, Cellular...

Cytomegalovirus Treatment Market Research Insights 2019 Global Industry Outlook Shared in Detailed Report, Forecast to 2026 – 3rd Watch News

By Stem Cell Treatment

The global Cytomegalovirus Treatment market is forecasted to reach a market value of ~US$ XX Mn/Bn by the end of 2029 registering a CAGR growth of around XX% during the forecast period (2019-2029). The recent market report provides a detailed analysis of the current structure of the Cytomegalovirus Treatment market along with the estimated trajectory of the market over the course of the stipulated timeframe.

The report provides an in-depth assessment of the numerous factors that are anticipated to impact the market dynamics with utmost precision and accuracy. The SWOT and Porters Five Forces Analysis provides a clear picture about the current operations of the various market players operating in the global Cytomegalovirus Treatment market.

Request Sample Report @https://www.mrrse.com/sample/19063?source=atm

The Cytomegalovirus Treatment market report portrays the market share and the application of each of the sub-segments across various verticals.

The Cytomegalovirus Treatment market report explains how the Cytomegalovirus Treatment is being deployed in different sector.

Competitive landscape:

The report ponders over the market scenario in various geographies and highlights the major opportunities, trends, and challenges faced by market players in each region. An in-depth country wise analysis of each major region provides readers a deep understanding of the regional aspects of the market including, the market share, pricing analysis, revenue growth, and more.

Competitive Assessment

This chapter includes a comprehensive list of all the leading manufacturers in the Cytomegalovirus treatment market, along with detailed information about each company, including company overview, revenue share, strategic overview, and recent company developments. Market players featured in the report include Merck & Co. Inc, Mylan N.V., Chimerix, Inc., Thermo Fisher Scientific, Abbott, Becton, Dickinson and Company, Johnson & Johnson, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Pfizer and among others

Chapter 15 Global Cytomegalovirus Treatment Market Analysis 2013-2017 and Opportunity Assessment 2018-2028 by Region

This section highlights Cytomegalovirus treatment in the overall global market by value (US$ Mn) forecast and analysis, by region such as North America, Latin America, Western Europe, Eastern Europe and Asia Pacific Including Japan, China and MEA.

Chapter 16 Global Cytomegalovirus Treatment Market Analysis 2013-2017 and Opportunity Assessment 2018-2028 by Drug Type

Based on drug type market analysis, the Cytomegalovirus treatment market is segmented into Ganciclovir, valganciclovir, Foscarnet, Cidofovir and other.

Chapter 17 Global Cytomegalovirus Treatment Market Analysis 2013-2017 and Opportunity Assessment 2018-2028 by Application

Based on Application, the Cytomegalovirus treatment market is segmented into Stem Cell Transplantation, Organ Transplantation, Congenital CMV infection and others.

Chapter 18 Global Cytomegalovirus Treatment Market Analysis 2013-2017 and Opportunity Assessment 2018-2028 by Distribution Channel

Based on distribution channel, the Cytomegalovirus treatment market is segmented into hospital pharmacies, retail pharmacies, drugstores, and e-Commerce.

Chapter 19 Global Cytomegalovirus Treatment Market Analysis 2013-2017 and Opportunity Assessment 2018-2028

This section highlights the overall global market value (US$ Mn) forecast and analysis of the Cytomegalovirus treatment market, with detailed incremental opportunity and absolute opportunity.

Chapter 20 Assumptions and Acronyms Used

This section consists of a glossary of the assumptions and acronyms used in the Cytomegalovirus treatment market report.

Chapter 21 Research Methodology

This chapter helps readers understand the research methodology that is followed to obtain various conclusions, important qualitative information, and quantitative information about the Cytomegalovirus treatment market.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/19063?source=atm

The market report on the Cytomegalovirus Treatment market addresses some important questions such as:

Crucial data enclosed in the report:

Buy This Report @ https://www.mrrse.com/checkout/19063?source=atm

Go here to see the original:
Cytomegalovirus Treatment Market Research Insights 2019 Global Industry Outlook Shared in Detailed Report, Forecast to 2026 - 3rd Watch News

The International Space Station creates bigger, colder states of matter than are possible on Earth – Massive Science

By Stem Cell Doctors

Eight years ago, I was packing my home and entire life in Mexico to move to the US to pursue a PhD in Ecology and Evolutionary Biology at the University of California-Irvine. Those were easier times, although it did not seem like it at the time. I spent a few months worth of income to pay for paperwork to apply for an F-1 student visa, and to pay for other documents to enroll as a graduate student. This was after I dedicated months to emailing professors everywhere in the US, hoping that one of them would reply to my email and would invite me to apply to join their lab. It was also after spending time and money paying for standardized tests, official document translations, and application fees. It was a one-and-a-half-year process but in July 2012, I was finally moving to the USA to pursue my PhD. It was a dream come true.

It was also a dream come true for the University of California because I had a full scholarship from my home country that paid for the entirety of my international tuition and fees, which were around $35,000 per year. My scholarship allowed me to pursue my PhD in the USA, and to UC Irvine it provided basically free labor as well as prestige.

I paid taxes and did all of the typical graduate student responsibilities. I also dedicated a lot of my time to doing outreach to bring science to underserved communities around Orange County and Southern California. By the time I graduated in 2017, I was a stellar student, with three publications with UC Irvine's name on them. I co-organized summer science camps for middle school girls that brought money and a good reputation to my university and program. I mentored students of all ages. I was a good citizen of my program, of my university, and of Orange County.

Like me, most international students leave their families and everything that they are comfortable with to pursue the dream of graduate school. They bring with them the hope of being welcomed and treated fairly by their American peers. I have experienced this, but I am one of the lucky ones.

It is no secret that international students and postdocs will withstand abuse and other injustices just so they can keep their visa, which is always tied to their university. Many universities receive international students without having a system to deal with the unique challenges that international students face, such as having no credit history, which complicates finding a place to live and leaves international students vulnerable to landlord abuse. Many international students are people of color, and universities, especially predominantly white institutions, do not have resources to ensure safety of these students within the university and in the community at large.

These challenges are further complicated due to a lack of community and support. Making friends in the US, especially if you are coming from Global South countries and/or non-Westernized countries, is extremely challenging. Many times, I have seen how western Europeans, Australians, and Canadians are rapidly accepted in the local community, while many Latinx, Asians, and Middle-Easterners are not.

There are over one million international students in the US. The ICE Student Ban may no longer be a threat, but universities still need to change how they handle international students. We are people too, but many universities have historically valued us only by the amount of money we bring. We improve higher education not only by the money that we bring, but by our unique perspectives, our research productivity, and our willingness to give back to American society.

See the original post:
The International Space Station creates bigger, colder states of matter than are possible on Earth - Massive Science

Gene Therapy Market Size Is Expected to Grow at a CAGR of 40.7% By 2025 | Share Analysis, Growth Outlook, COVID-19 Impact and Size Estimation -…

By Gene Therapy Clinics

(MENAFN - iCrowdNewsWire) Jul 17, 2020

Gene Therapy Market Research Report: By Product (Kymriah, Luxturna, Yescarta, Zolgensma, Strimvelis, Zynteglo, Others), By Indication (Oncology, Genetic Diseases, Others) and By End-User (Hospitals & Clinics, Specialty Treatment Centers), Forecast to 2025

Gene Therapy Market Landscape

The Gene Therapy Market size in 2018 was valued at USD 524 million. It is likely to grow at a whopping 40.7% CAGR by 2025, as per the Market Research Future's (MRFR) new report. Gene therapy comprises replacing, repressing, and repairing dysfunctional genes that cause disease. The aim of this promising treatment is in re-establishing the normal function. This therapy helps to treat different genetic diseases such as inherited disorders, namely cancer & viral infections, and some specific genetic diseases, namely muscular dystrophy & cystic fibrosis.

Numerous factors are propelling the global gene therapy market growth. These factors, as per the new MRFR report, comprise increasing funds for gene therapy research, availability of favourable reimbursements, increasing cases of cancer & other target diseases, and strategic collaborations & product launches made by key players for staying ahead in the competition. Besides, rising cases of target diseases, large investments made by top market players, and robust product pipeline are also adding gene therapy market growth.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8399

On the contrary, strict regulatory policies coupled with high product development cost are factors that may deter the gene therapy market growth over the forecast period as per the gene therapy market forecast.

Gene Therapy Market Segmentation

The global gene therapy market has been segmented based on indication, product, and end user.

By product, the gene therapy market is segmented into yescarta, zynteglo, luxturna, imlygic, kymriah, zolgensma, strimvelis, and others.

By indication, the gene therapy market is segmented into oncology, genetic disorders/diseases, and others. Among these, the oncology segment will have a major share in the market over the forecast period. The robust cancer gene therapy pipeline, coupled with surging cancer cases, is adding to the growth of the segment.

By end user, the gene therapy market is segmented into hospitals and clinics, the specialty treatment centre, & others. Among these, hospitals & clinics will lead the market over the forecast period. The burgeoning number of hospitals, coupled with hospitals & clinics being the foremost choice to treat diseases, is boosting the growth of this segment.

Gene Therapy Market Regional Analysis

Based on the region, the global gene therapy market report covers the recent trends and growth opportunities across Europe, North America, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, North America will have lions share in the market over the forecast period for the rising cases of chronic diseases, increasing healthcare expenditure, advanced & innovative healthcare infrastructure, presence of eminent market players, and availability of favorable reimbursements.

The global gene therapy market in Europe is predicted to have favorable growth over the forecast period for industry players coming up with innovative product launches, top companies in the region extending product distribution by securing approval from various regulatory bodies, and increasing expenditure for gene and cell therapy companies in the UK.

The global gene therapy in the Asia Pacific region is likely to grow at a fast pace during the forecast period. The rising government initiatives for the healthcare sector development, presence of top market players in the region, launch & approval of various gene therapy products, rising prevalence of chronic diseases, and growing awareness about gene therapy are adding market growth.

The global gene therapy market in the Middle East and Africa is predicted to hold the smallest share over the forecast period for restricted healthcare infrastructure in the region.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/gene-therapy-market-839

Gene Therapy Market Key Players

Eminent players in the global gene therapy market include Orchard Therapeutics plc (UK), Novartis AG (Switzerland), Lonza (Switzerland), CEVEC (Germany), Amgen, Inc. (US), Gilead Sciences, Inc. (US), Thermo Fisher Scientific Inc. (US), Spark Therapeutics, Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US),and uniQure N.V (Netherlands).

Table Of Contents

Chapter 1. Report Prologue

Chapter 2. Gene Therapy Market Introduction

Definition

Scope Of The Study

Research Objective

Assumptions

Limitations

Chapter 3. Research Methodology

Introduction

Primary Research

Secondary Research

Market Size Estimation

Chapter 4. Gene Therapy Market Dynamics

Drivers

Restrains

Opportunities

Challenges

TOC Continued

Browse More Healthcare Research Reports at:

Intraoperative Neurophysiological Monitoring Market Trends, Size and Application, By Type (EEG, EMG and Evoked Potential (EP)), Method (Invasive, Non-Invasive and Minimally Invasive), Source (In-house, Outsource and Tele-Health), Procedure (Spinal, Neurovascular, Orthopedic, Otolaryngology Surgery, Urology and others) and Region (North America, Europe, Asia-Pacific and the Middle East & Africa) - Forecast to 2027 https://www.marketresearchfuture.com/reports/intraoperative-neurophysiological-monitoring-market-729

Healthcare IoT Security Market Research Report: Information by Component (Solution and Services), Solutions Type (Analytics, Encryption, Data Loss Protection, Identity and Access Management and Unified Threat Management), Service Type (Consulting Services, Risk Assessment Services, Design & Integration Services and Managed Security Services), Security Type (Application, Cloud, Endpoint and Network), Application (Pharmaceutical, Medical Devices and Biotechnology) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025 https://www.marketresearchfuture.com/reports/healthcare-iot-security-market-946

Ultra-low Temperature Freezers Market: Information by Type (Upright, Chest), Degree of Cooling (-41C to -86 C Freezers, -87C to -150 C Freezers), Application (Blood & Blood Products, Biological Samples, Drug Compounds, Others), End-User (Bio-Banks, Hospitals & Clinics, Academic & Research Laboratories, Others) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027 https://www.marketresearchfuture.com/reports/ultra-low-temperature-freezer-market-1813

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Here is the original post:
Gene Therapy Market Size Is Expected to Grow at a CAGR of 40.7% By 2025 | Share Analysis, Growth Outlook, COVID-19 Impact and Size Estimation -...

Choroideremia Treatment Market Business Growth by Copernicus Therapeutics, Inc, Wize Pharma Inc, Spark Therapeutics, Inc – 3rd Watch News

By Gene Therapy Clinics

Data Bridge Market Researchhas added an exhaustive research study of theGlobal Choroideremia Treatment Marketdetailing every single market driver and intricately analyzing the business vertical. The research report has abilities to raise as the most significant market worldwide as it has remained playing a remarkable role in establishing progressive impacts on the universal economy. The research report presents a complete assessment of the market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data.

Global Choroideremia Treatment Marketis expected to grow at a steady CAGR in the forecast period of 2019-2026.Increase in strategic alliances between the pharmaceuticals companies and high demand of disease specific novel therapies are the key factors that fueling the market growth. Global Choroideremia Treatment Market By Treatment Type (Gene Therapy, Surgery), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Ophthalmic Clinics and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Forecast to 2026

Download exclusive PDF sample report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-choroideremia-treatment-market

Some of the major competitors currently working in the global choroideremia treatment market areBiogen, 4D Molecular Therapeutics, Copernicus Therapeutics, Inc, Wize Pharma Inc, Spark Therapeutics, Inc, PIXIUM VISION, Retina Implant AG, F. Hoffmann-La Roche Ltd and others.

Market Definition:

Choroideremia is also known as choroidal sclerosis is a rare, degenerative, X-linked inherited retinal disorder characterized by progressive degeneration of the choroid, retinal pigment epithelium (RPE) and retina due to Mutations in the CHM gene. This CHM gene required to produce Rab escort protein-1 (REP-1). The condition gets its name from the distinctive sweet odor of affected infants urine and is also c, a protein that takes part in targeting vesicles (small sacs of substances) into, out of, and within cells.

According to the statistics published by U.S. Department of Health & Human Services, an estimated population of choroideremia is about 1 in 50,000-100,000 people. Presence of refined healthcare infrastructure and emerging new market are the key factors for growth of this market.

Market Drivers

Market Restraints

Segmentation:Global Choroideremia Treatment Market

By Treatment

By Route of Administration

By End Users

By Distribution Channel

ByGeography

Download Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-choroideremia-treatment-market

Key Developments in the Market:

Competitive Analysis:

Global choroideremia treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares global choroideremia treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

Order a Copy of Global Choroideremia Treatment Market Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-choroideremia-treatment-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

View original post here:
Choroideremia Treatment Market Business Growth by Copernicus Therapeutics, Inc, Wize Pharma Inc, Spark Therapeutics, Inc - 3rd Watch News

These were the worst performing ASX 200 shares last week – Motley Fool Australia

By Stem Cell Medicine

Motley Fool Australia Share Fallers These were the worst performing ASX 200 shares last week

James Mickleboro | July 18, 2020 8:46am | More on: AVH MP1 MSB PNV ASX 200

The S&P/ASX 200 Index(ASX: XJO) was back on form last week and stormed through the 6,000 points level once again. The benchmark index climbed 1.9% to 6033.6 points.

Unfortunately, not all shares were able to climb higher with the market. Heres why these were the worst performing ASX 200 shares last week:

TheAVITA Therapeutics Inc(ASX: AVH)share price was the worst performer on the ASX 200 last week and crashed 19% lower. This follows the release of the regenerative medicine companys fourth quarter and full yearsales update. For FY 2020, AVITAs total revenue came in at approximately US$14.32 million. While this was a sizeable increase of US$8.78 million or 160% over FY 2019s sales, it appears as though investors were expecting an even stronger sales result.

TheMesoblast limited(ASX: MSB) share price was some way behind with a 9.5% decline last week. This appears to have been driven by profit taking after some very strong gains. In fact, a week earlier the allogeneic cellular medicines developers shares were among the best performers. Investors were fighting to buy shares after it provided an updateon its allogeneic mesenchymal stem cell (MSC) product candidate, remestemcel-L. That update revealed that remestemcel-L has been given an expanded access protocol for compassionate use in the treatment of COVID-19 infected children with cardiovascular and other complications of multisystem inflammatory syndrome.

ThePolyNovo Ltd(ASX: PNV)share price was out of form last week and tumbled 7% lower. Once again, this appears to have been down to profit taking after strong gains in previous months. For example, even after last weeks declines, PolyNovos shares are still up over 35% since the start of the year.

The Megaport Ltd (ASX: MP1) share price was a poor performer last week and recorded a 6.9% decline. It appears as though investors were rotating funds out of the tech sector over the period. The provider of elastic interconnection services across data centres wasnt the only tech share taking a tumble. The S&P/ASX 200 Information Technology index ran out of steam last week and fell 3.5% despite the ASX 200 pushing 1.9% higher.

5 stocks under $5

We hear it over and over from investors, "I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I'd be sitting on a gold mine!" And it's true.

And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

See the 5 stocks

*Extreme Opportunities returns as of June 5th 2020

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Avita Medical Limited, MEGAPORT FPO, and POLYNOVO FPO. The Motley Fool Australia has recommended Avita Medical Limited and MEGAPORT FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

James Mickleboro has been a Motley Fool contributor since late 2015. After studying economics at university back home in the United Kingdom, James came to live in Australia and managed to land a job at an Australian fund manager. This was the start of a love affair with Australian equities and he hasnt looked back since. James is part of the CFA Institutes Chartered Financial Analyst program and hopes it teaches him how to become an astute investor which allows him to help others with their own investing. Outside of reading and researching he spends many a late night watching the English Premier League and Seinfeld reruns.

Visit link:
These were the worst performing ASX 200 shares last week - Motley Fool Australia

Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab – Business Wire

By Stem Cell Clinic

SOMERSET, N.J. & BURLINGAME, Calif.--(BUSINESS WIRE)--Catalent and Humanigen, Inc. (HGEN) (Humanigen) today announced the expansion of their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab, Humanigens proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody.

Catalent is the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies and consumer health products. Humanigen is a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the companys lead therapeutic candidate.

Mayo Clinic recently announced data on the first clinical use of lenzilumab in 12 patients with severe and critical COVID-19 pneumonia, the majority of whom showed rapid recovery and hospital discharge. A Phase 3 study is currently underway evaluating hospitalized COVID-19 patients.

Based on lenzilumabs promising clinical data, we are pleased to expand our relationship with Catalent to solidify our ability to manufacture and supply lenzilumab, commented Cameron Durrant, MD, MBA, Chief Executive Officer of Humanigen. If we are able to secure FDA approvals or Emergency Use Authorization, Catalent Biologics deep expertise and integrated OneBio solution will accelerate our ability to get this therapy to patients that need it most.

Catalent has partnered closely with Humanigen to develop and supply lenzilumab for clinical trials, commented Karen Flynn, President of Catalent Biologics and Chief Commercial Officer. The experience we already have with lenzilumab, and our OneBio integrated offering from development to supply, make Catalent uniquely suited to support Humanigen in the journey to make this promising therapy available to COVID-19 patients as soon as possible following receipt of regulatory approvals.

To date, Catalent Biologics has provided early-stage development and clinical cGMP drug substance manufacturing for lenzilumab at its facility in Madison, Wisconsin to support Humanigens ongoing clinical trials across various disease categories. Under the expanded partnership, Catalent is also providing clinical supply support for Humanigens Phase 3 potential registration study in COVID-19 from its Philadelphia facility.

Lenzilumab was originally manufactured in Catalents Madison facility using Catalent Biologics proprietary GPEx cell line development technology. As part of the expanded partnership, Catalent intends to provide additional drug substance clinical supply for Humanigens clinical trials, Expanded Access Program (EAP), as well as additional late-stage development and clinical and potential commercial drug substance manufacturing and vial filling at its Madison and Bloomington, Indiana, sites.

Catalent Biologics Madison facility provides development and drug substance manufacturing, including GPEx cell line development, process development, process validation, formulation development, and clinical and commercial cGMP manufacturing. Its Bloomington facility has deep expertise in sterile formulation, with drug substance development and manufacturing and drug product fill/finish capacity across liquid and lyophilized vials, prefilled syringes, and cartridges as well as primary and secondary packaging.

Catalents OneBio Suite is an integrated solution for the development, manufacturing, and supply of biologic drugs. Launched in May 2019, the suite of offerings is designed to integrate activities and accelerate timelines, reduce risk and simplify development with a single contract, program manager, and development timeline from cell line development to supply, with harmonized quality systems.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The companys immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit http://www.humanigen.com.

About Catalent Biologics

Catalent Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates. With over 20 years of proven expertise, Catalent Biologics has worked with 600+ mAbs and 80+ proteins, produced 13 biopharmaceutical drugs using GPEx cell line development technology, and manufactured 35+ commercially approved products. Catalent Cell & Gene Therapy, a unit of Catalent Biologics, is a full-service partner for adeno-associated virus (AAV) vectors and CAR-T immunotherapies, with deep experience in viral vector scale-up and production. Catalent recently acquired MaSTherCell, adding expertise in autologous and allogeneic cell therapy development and manufacturing. Catalent Cell & Gene Therapy has produced 100+ cGMP batches across 70+ clinical and commercial programs. For more information, visit biologics.catalent.com.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, manufacturing, and clinical supply solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.

Humanigens Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations for the Phase III study and the potential future development of lenzilumab to minimize or reduce the severity of lung dysfunction associated with severe and critical COVID-19 infections or to be approved by FDA for such use or to help CAR-T reach its full potential or to deliver benefit in preventing GvHD. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to conduct the Phase III study and grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

Here is the original post:
Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab - Business Wire

NCRM NICHE International Stem Cell meet is going virtual in 2020 – THE WEEK

By Stell Cell Research

(Eds: Disclaimer: The following press release comes to you under an arrangement with MediaWire. PTI takes no editorial responsibility for the same.) Active Knowledge Gaining event Fujio Cup Quiz (FCQ) in Japan, open to global talents

Tokyo, 15, July, 2020: The XV edition of NCRM NICHE (www.ncrmniche.org), on Stem Cells and Regenerative Medicine, incorporating the exclusive, active knowledge gaining event, The Fujio Cup Quiz, conducted regularly since 2006 every October, will be conducted this year as a virtual event, opening doors for scholars from all over the world to participate, according to the organizers, M/s GN Corporation (GNC) & JBM Inc., Japan.

Two levels of prelims between 2nd ~ 20th August and the final rounds of the Fujio Cup Quiz (FCQ) between 1st to 30th September, will be conducted through a virtual platform. The winners will share their winning story along with a presentation on stem cell research on the 18th & 19th October 2020, during the NCRM NICHE event, the inaugural anniversary commemorative event of Nichi-In Centre for Regenerative Medicine (NCRM), a Japan centred research institute working on cell-based therapies and novel biomaterial technologies. The Organizers are planning to invite the winners of the Fujio Cup 2020 to Japan depending on the ease down of COVID-19 related restrictions, tentatively in 2021, when they will be visiting top institutes working on cutting edge technologies in regenerative medicine in Tokyo, including the Edogawa Evolutionary Lab of Science (EELS, http://www.eels.tokyo).

The rapidly evolving specialty of regenerative medicine has phenomenal potentials to yield novel solutions to unmet medical needs; is an inter-disciplinary field in which chemists making scaffolds, physicists working on physical forces and biologists working on cell culture and tissue engineering have to collaborate amongst themselves and with physicians of various clinical specialities to develop innovative treatment options. Such path-breaking solutions need to be developed over a period of time, through ceaseless interactions among scientists of various domains & NCRM NICHE has been serving continuously as a platform for such inter-disciplinary interaction among budding scientists and clinicians over the past 15 years. Osteoarthritis affected knee joint of elderly, yielding cartilage tissue expressing pluripotency biomarkers when grown in the lab (https://doi.org/10.1016/j.reth.2020.03.006), is an out of the box solution with numerous potentials to revolutionize cell therapy options for cartilage damage caused by sports injury as well that develops with age related wear and tear; an outcome of NCRM NICHE & Fujio Cup Quiz, according to Dr. Shojiro Katoh, Chief Orthopaedic Surgeon & President, Edogawa Hospitals and head of EELS.

Yesteryear participants of Fujio Cup Quiz have become scholars of prestigious institutes of global eminence including Massachusetts General Hospital and Harvard Medical School, University of Toronto, MD Anderson Cancer Center, Berlin-Brandenburg School for Regenerative Therapies & Tokyo University. Fujio Cup Quiz alumni also have a priority channel for nomination of the Edogawa NICHE prize (www.edogawanicheprize.org), award, established in 2018, which honours individuals who are physicians and/or scientists from around the world chosen by the Jinseisha-NCRM committee, based on their contribution to development of a novel solution that enables prevention or diagnosis or treatment of any disease, through an inter-disciplinary interaction among different fields of science. The 2018 Edogawa NICHE Prize was awarded to Prof. James Edgar Till for his discovery of stem cells & the 2019 Edogawa NICHE Prize was awarded to Dr. Steven A. Rosenberg, for his pioneering work in developing effective adoptive immunotherapies to tackle cancer. The recipient of 2020 Edogawa NICHE Prize will be announced on the 15th of August and the commemorative lecture of the awardee is also planned together with the visit of FCQ winners to Japan in 2021.

Undergraduate, Postgraduate and Doctoral (PhD) students of Life Sciences, Biotechnology, Veterinary Science, Dentistry and Medicine between the ages of 20 and 32 years, registered in an accredited academic institute from any country that is a member state of the United Nations (UN) are eligible to participate in the Fujio Cup Quiz (FCQ). NCRM NICHE has an Oral Presentation session, in which all original works on Basic Sciences, Translational Studies and Clinical studies in the field of Stem Cells and Regenerative Medicine including the allied fields of Cell Biology, Cancer Biology, Immunotherapy and Cell based therapies are eligible for submission as abstracts. Selected abstracts will have an opportunity for virtual presentation on 18th & 19th of October, 2020.

30th of July, 2020 is the deadline for submission of abstracts & FCQ registration. Further details at https://www.ncrmniche.org/ncrmniche2020/registration.html

Prof. Masaharu Seno from Okayama University, Japan working on Development of Cancer stem cells from induced pluripotent stem cells (iPSCs) prepared from fibroblasts and Dr. Maria Cristina Nostro from University of Toronto working on generating functional cells from human pluripotent stem cells will be delivering virtual lectures in the plenary session of the event scheduled on 18th of October, 2020.

Institutes who wish to send their students and scholars for participation in the event and also those who wish to have a live broadcast of this event in their institute or to their students through their virtual platforms may contact us at webmaster@ncrmniche.org

The XIII edition of Fujio Cup Quizs Winners, Ms. Grace Aprilia Helena & Mr. Tommy Octavianus from Bandung Institute of Technology, Indonesia, receiving the ever-rotating cup from Dr Masahiro Katoh Chairman, Edogawa Hospital & Jinseisha Social Welfare Trust in Tokyo, Japan PWR PWR

Read more:
NCRM NICHE International Stem Cell meet is going virtual in 2020 - THE WEEK

Animal Stem Cell Therapy Market size and Key Trends in terms of volume and value 2019-2025 – 3rd Watch News

By Stem Cell Treatment

Animal Stem Cell Therapy Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The recent published research report sheds light on critical aspects of the global Animal Stem Cell Therapy market such as vendor landscape, competitive strategies, market drivers and challenges along with the regional analysis. The report helps the readers to draw a suitable conclusion and clearly understand the current and future scenario and trends of global Animal Stem Cell Therapy market. The research study comes out as a compilation of useful guidelines for players to understand and define their strategies more efficiently in order to keep themselves ahead of their competitors. The report profiles leading companies of the global Animal Stem Cell Therapy market along with the emerging new ventures who are creating an impact on the global market with their latest innovations and technologies.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2726754&source=atm

The recent published study includes information on key segmentation of the global Animal Stem Cell Therapy market on the basis of type/product, application and geography (country/region). Each of the segments included in the report is studies in relations to different factors such as market size, market share, value, growth rate and other quantitate information.

The competitive analysis included in the global Animal Stem Cell Therapy market study allows their readers to understand the difference between players and how they are operating amounts themselves on global scale. The research study gives a deep insight on the current and future trends of the market along with the opportunities for the new players who are in process of entering global Animal Stem Cell Therapy market. Market dynamic analysis such as market drivers, market restraints are explained thoroughly in the most detailed and easiest possible manner. The companies can also find several recommendations improve their business on the global scale.

The readers of the Animal Stem Cell Therapy Market report can also extract several key insights such as market size of varies products and application along with their market share and growth rate. The report also includes information for next five years as forested data and past five years as historical data and the market share of the several key information.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2726754&source=atm

Segment by Type, the Animal Stem Cell Therapy market is segmented into Dogs Horses Others

Segment by Application, the Animal Stem Cell Therapy market is segmented into Veterinary Hospitals Research Organizations

Regional and Country-level Analysis: North America United States Canada Asia-Pacific China Japan South Korea India Southeast Asia Australia Rest of Asia-Pacific Europe Germany France U.K. Italy Russia Nordic Countries Rest of Europe Latin America Mexico Brazil Rest of Latin America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA

Competitive Landscape and Animal Stem Cell Therapy Market Share Analysis Animal Stem Cell Therapy market competitive landscape provides details and data information by companies. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on sale and revenue by players for the period 2015-2020. Details included are company description, major business, Animal Stem Cell Therapy product introduction, recent developments, Animal Stem Cell Therapy sales by region, type, application and by sales channel.

The major companies include: Medivet Biologics LLC VETSTEM BIOPHARMA J-ARM U.S. Stem Cell, Inc VetCell Therapeutics Celavet Inc. Magellan Stem Cells Kintaro Cells Power Animal Stem Care Animal Cell Therapies Cell Therapy Sciences Animacel

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2726754&licType=S&source=atm

Some of the Major Highlights of TOC covers in Animal Stem Cell Therapy Market Report:

Chapter 1: Methodology & Scope of Animal Stem Cell Therapy Market

Chapter 2: Executive Summary of Animal Stem Cell Therapy Market

Chapter 3: Animal Stem Cell Therapy Industry Insights

Chapter 4: Animal Stem Cell Therapy Market, By Region

Chapter 5: Company Profile

And Continue

Go here to see the original:
Animal Stem Cell Therapy Market size and Key Trends in terms of volume and value 2019-2025 - 3rd Watch News

Duchenne Muscular Dystrophy Treatment Market Research Report 2020-2024 | Analysis by Key Regions, Manufacturing Technology and Development Forecast …

By Stem Cell Treatment

Sarepta Therapeutics

Scope of the Report:

As per the , Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. It is a rare muscle disease, which majorly affects males. There are novel drugs and therapies, disease-modifying, and mutation-specific therapies that are some of the emerging major breakthroughs in the DMD treatment market.

The Report Covers:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/13999594

Key Market Trends:

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Segment is Expected to Grow Fastest During the Forecast Period

Corticosteroids are the only known pharmacological treatment for DMD and help to suppress muscle inflammation. This treatment is being limited by its inadequate therapeutic efficacy, and considerable side effects, and hence, non-steroidal anti-inflammatory drugs (NSAIDs) can be used to reduce the inflammation of muscles. The nonsteroidal anti-inflammatory drugs are expected to witness a CAGR of 49.2% over the forecast period.

However, other therapies and treatments include stem cell therapy, repurposing drugs, anti-fibrotics, myostatin inhibition, gene editing (CRISPR/Cas9), etc. Currently, prednisone/prednisolone and deflazacort have been used for the treatment of Duchenne muscular dystrophy, which is expected to drive the growth of the market, over the forecast period.

North American Region holds the Largest Market Share of the Market Currently and is Believed to Follow the Same Trend Over the Forecast Period

North America dominates the global Duchenne muscular dystrophy market, due to new product innovations, high healthcare expenditure, and government awareness programs. The United States has dominated the regional market and is projected to maintain its lead, owing to the rising disease incidence and anticipated launch of promising pipeline candidates. In addition, the market is expected to grow with the increasing clinical trials around the world, especially in the United States and Europe.

Key Questions Answered in This Report:

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/13999594

Detailed TOC of Duchenne Muscular Dystrophy Treatment Market 2019-2024:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Rising Disease Burden of Duchenne Muscular Dystrophy (DMD) 4.2.2 Increasing Investments in Biopharmaceutical R&D to Release Novel Disease Therapies 4.2.3 Increasing Awareness Campaigns for DMD 4.3 Market Restraints 4.3.1 Lack of Standardization to Measure Clinical Efficacy Across All Stages of DMD 4.3.2 Stringent Regulatory Framework with High Product Cost Burden 4.4 Porters Five Forces Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Therapeutic Approach and Treatment Type 5.1.1 Molecular-based Therapies 5.1.1.1 Mutation Suppression 5.1.1.2 Exon Skipping 5.1.2 Steroid Therapy 5.1.2.1 Corticosteroids 5.1.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) 5.1.4 Other Therapeutic Approaches and Treatment Types 5.2 By End User 5.2.1 Hospitals/Clinics 5.2.2 Ambulatory Centers 5.2.3 Other End Users 5.3 Geography 5.3.1 North America 5.3.1.1 United States 5.3.1.2 Canada 5.3.1.3 Mexico 5.3.2 Europe 5.3.2.1 Germany 5.3.2.2 United Kingdom 5.3.2.3 France 5.3.2.4 Italy 5.3.2.5 Spain 5.3.2.6 Rest of Europe 5.3.3 Asia-Pacific 5.3.3.1 China 5.3.3.2 Japan 5.3.3.3 India 5.3.3.4 Australia 5.3.3.5 South Korea 5.3.3.6 Rest of Asia-Pacific 5.3.4 Middle East & Africa 5.3.4.1 GCC 5.3.4.2 South Africa 5.3.4.3 Rest of Middle East & Africa 5.3.5 South America 5.3.5.1 Brazil 5.3.5.2 Argentina 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 BioMarin 6.1.2 Bristol-Myers Squibb Company 6.1.3 Fibrogen Inc. 6.1.4 Eli Lilly and Company 6.1.5 Nobelpharma Co. Ltd 6.1.6 NS Pharma Inc. 6.1.7 Pfizer Inc. 6.1.8 PTC Therapeutics 6.1.9 Santhera Pharmaceuticals 6.1.10 Sarepta Therapeutics

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Quantum Sensors Market 2020 Trends, Manufacturing Size, Growth Analysis by Share, Top Regions, Driving Factors of Manufacturers, Types and Applications Forecast to 2023

Cell Culture Reagent Market Size and Growth Rate 2020 | Global Impact of COVID-19 on Industry Share, Explosive Factors of Key Players, Progress Status, and Recent Trends Forecast to 2026

Polymer Stabilizing Agent Market Size and Growth Rate 2020 | Global Impact of COVID-19 on Industry Share, Explosive Factors of Key Players, Progress Status, and Recent Trends Forecast to 2026

Split Case Pumps Market Size by Top Key Players 2020 Global Growth Rate by Share, Industry Segment, Future Prospect, Key Finding and Market Dynamics Forecast to 2026

Liquid Chromatography-Mass Spectroscopy Market Growth Analysis by Top Key Players 2020 Consumption Capacity by Volume and Production Value, Trends Analysis, and Company Profiles till 2025

Read more here:
Duchenne Muscular Dystrophy Treatment Market Research Report 2020-2024 | Analysis by Key Regions, Manufacturing Technology and Development Forecast ...

→←